A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas

Sponsor
Clinical Research Center for Solid Tumor, Korea
Study ID
NCT00921167
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab/Irinotecan — DRUG
    Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs \[EIAEDs\] or 340mg/m2 for patients on EIAEDs) every 2 weeks

Study Details

To assess the efficacy and safety of bevacizumab plus irinotecan for the patients with recurrent anaplastic astrocytoma or with recurrent glioblastoma multiforme

Key Dates

Start date
Jun 30, 2009
Status verified
Dec 2013
Primary completion
Jun 30, 2012
Completion
Dec 31, 2013

Study Design

Enrollment
32 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab/Irinotecan

Primary Outcome Measure

Progression-free survival [ Time Frame: 6 months, 1 year ]

Related Studies